January 6, 2023 10:26 AM EST

Six years later, SEC drops claims of accounting fraud against biotech exec

Amber Tong

The US Securities and Exchange Commission has dropped its claims against the former CEO of Osiris Therapeutics, who was accused of lying about the regenerative …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Six years later, SEC drops claims of accounting fraud against biotech exec

Amber Tong

Sign up to read this article for free.

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Six years lat­er, SEC drops claims of ac­count­ing fraud against biotech ex­ec

Amber Tong

Sign up to read this article for free.

more like this

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Six years later, SEC drops claims of accounting fraud against biotech exec

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved